Hims stock fell after the FDA said its GLP-1 product may no longer be in shortage and a competitor reported disappointing GLP-1 news. Is the stock's drop an overreaction?

For long-term investors, I think it is.
-----------------------------------------------------------------------------------------------------

💰 If you like this video, check out my free Asymmetric Investing Newsletter for more investment analysis: [ Ссылка ]
TRAVIS ON TWITTER: [ Ссылка ]

Check out Public.com's bond product here: [ Ссылка ]

📊 The charts I use are made with FinChat, the best tool for investment research. I pay for the Pro plan, but you can get started making beautiful charts and asking the AI questions here: [ Ссылка ]

Disclosure:
A Bond Account is a self-directed brokerage account with Public Investing, member FINRA/SIPC. Deposits into this account are used to purchase 10 investment-grade and high-yield bonds. As of 9/26/24, the average, annualized yield to worst (YTW) across the Bond Account is greater than 6%. A bond's yield is a function of its market price, which can fluctuate; therefore, a bond's YTW is not "locked in" until the bond is purchased, and your yield at time of purchase may be different from the yield shown here. The "locked in" YTW is not guaranteed; you may receive less than the YTW of the bonds in the Bond Account if you sell any of the bonds before maturity or if the issuer defaults on the bond. Public Investing charges a markup on each bond trade. See our Fee Schedule. Bond Accounts are not recommendations of individual bonds or default allocations. The bonds in the Bond Account have not been selected based on your needs or risk profile. See [ Ссылка ] to learn more.

00:00 Market Reaction to HIMS and Hers Stock Drop
00:52 Understanding GLP-1 and Its Impact
01:16 Public.com
02:03 Latest News and FDA Updates
03:19 Future Prospects for HIMS and Hers
05:16 Conclusion and Final Thoughts

свернуть